我一起来梳理一下关于生物相似药或者说“生物仿制药”的一些资料
生物相似药受到越来越多的关注
Biosimilars – inflated expectations?
In October 2006, Senators Waxman, Schumer and Clinton introduced the “Access to Life-Saving
Medicines Act” to the US Congress in an attempt to establish an abbreviated application
process for biological products.
It was the same Senator Waxman who cooperated in 1984 with Senator Hatch to introduce
what became known as the Hatch-Waxman Act to introduce a simplified method of registration
for generics.
Before that, there had been virtually no generics market in the USA due to the massive barriers
to entry, which had made the process too difficult for cheap copies to enter the market. For
example, all new products had to provide the FDA with full toxicology and efficacy data, even
for molecules that were well established and well known.
Hatch-Waxman changed all this by allowing the FDA to refer to data filed by the originator and
requiring the generic applicant to merely provide all the necessary manufacturing data and
prove bioequivalence. This led to an explosion of cheap copies on to the market that in turn led
to vigorous price competition and the resulting cheap fall in prices, which was the aim of the
Act.
However, no such mechanism exists for biological medicines and their copies. For a long time,
the US generic industry has been pressing the FDA to introduce guidelines to allow them to
know how they can prove their biological product equivalent to the originator’s product. With
simple, chemically defined generic, this is a relatively straightforward process.
Take a healthy volunteer, give him or her a dose of the original product and measure the plasma
levels of the product over a certain period. Then repeat the process with the copy product,
compare the two blood levels and if they are more or less at the same level ± x%, then the two
products can be considered as bioequivalent.
With biological products, the picture becomes significantly more complicated as simple
bioequivalence will not do; some form of clinical equivalence must be established. Australia and
the EU have established guidelines and as a result have biosimilars based on Somatotropin on
their markets as do some East European and Asian countries. The FDA, however, has been
curiously reluctant to provide any such guidelines and this has resulted in the absence of any
biosimilar preparations on the US market. It was this situation that the Senators have set out to
remedy by forcing the FDA to move since it seems unwilling to do so of its own accord.
Biosimilar,引用王守业先生的说法,应该称为生物相似药。
个人更喜欢这种翻译。
What is biosimilar?
Biosimilars, also known as follow-on biologics, are biologic medical products whose active drug substance
is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods.
Biosimilars (or follow-on biologics) are terms used to
describe officially approved subsequent versions of innovator biopharmaceutical products made by a
different sponsor following patent and exclusivity expiry on the innovator product.
Biosimilar QuantiFERON-TB Gold的转阳率 - IFX或CT-P13 ? ? 在15个TB发生...<0.001 0.55 0.03 <0.001 -0.3 -1.0 参照 0.3 -1.3 0.4 -0...
Immunology PF-04236921 PH-797804 PF-06473871 (EXC 001) Xeljanz (tofacitinib...Biosimilar 6 Pfizer Pipeline – February 28, 2013 (cont’d) Therapeutic ...
●● 前12h,两者相似 12-24h,地特的GIR 降低速率显著快于甘精 (P<0.001)... 传统仿制药的规则不适用于生物制剂的仿制生物仿制药 Biosimilar 在原研生物制剂...
belimumab (subcutaneous) BHT-3009 BI-695500 (rituximab biosimilar) BI-695501...(KW-2871) EGEN-001 (Orphan Drug) breast cancer, ovarian cancer, prostate...
恩利?的临床疗效及安全性 1 2 3 相似 ≠ 相同 Biosimilar的定义 ? 欧洲药品...P<0.01, ?P<0.001 , EM/EM v M/M EM=恩利+甲氨碟呤 E=恩利 M=...
ed infectious disease product; biosimilar; discontinuation; withdrawal 5 药物的...艾西拉滨 (elacytarabine) ABH-001 阿格列扎 (aleglitazar) 普阿氯芬 (...
(hours) p<0.001 for all comparisons of AUC N=54 T1DM Heise T et al...on europa.eu/pdfs/human/biosimilar/043704en.pdf 美国FDA认识到生物仿制药物 ...
Canada add 5% GST #104911595RT001; Euro-zone: 202 (personal), 3,...30 number 3 march 2012 editorial 198 another nail in the biosimilar coffin...
Canada add 5% GST #104911595RT001; Euro-zone: 202 (personal), 3,...30 number 3 march 2012 editorial 198 another nail in the biosimilar coffin...
热门文档